xinbang phar.(SZ:002390) 中国基金报·2025-12-10 14:55Core Viewpoint - Xinfang Pharmaceutical is facing legal challenges due to allegations of unit bribery, which may adversely affect its brand reputation and future business development [6][8]. Group 1: Legal Issues - On December 10, Xinfang Pharmaceutical announced that it has been prosecuted by the procuratorial authority for suspected unit bribery, following materials sent by the supervisory committee [6][8]. - The company has received legal documents regarding the prosecution and is currently in the review and prosecution stage [6][8]. - Xinfang Pharmaceutical has stated that it will cooperate with relevant authorities and has appointed defense lawyers for the case [8]. Group 2: Stock Performance - On December 10, the stock price of Xinfang Pharmaceutical experienced a significant increase, reaching a limit up of 10.08%, closing at 4.15 yuan per share, with a total market value of 80.67 billion yuan [3][15]. Group 3: Financial Performance - For the first three quarters of the year, Xinfang Pharmaceutical reported revenue of 4.266 billion yuan, a year-on-year decrease of 6.55%, and a net profit attributable to shareholders of 152 million yuan, down 13.74% year-on-year [14]. - The company's financial performance has been unstable, with a projected decline of over 60% in net profit attributable to shareholders for 2024 [14].